Moderna (MRNA) Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/29/2026

1. LFTO
2. CMCSA
3. QNT
4. NVDA
5. VRDN
6. INIO
7. HONA
8. ABBV
9. HON
10. SPY

Go back to Moderna (MRNA) Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries

Moderna (MRNA) Announces FDA Requires Additional Time to Decide on Emergency Use Authorization of COVID-19 Vaccine for Adolescents

November 1, 2021 5:54 AM EDT

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update that the U.S. Food and Drug Administration (FDA) has notified the Company that it will require additional time to complete its assessment of Modernas Emergency Use Authorization (EUA) request for the use of the Moderna COVID-19 vaccine (mRNA-1273) at the 100 µg dose level in adolescents 12 to 17 years of age.

On... More